Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
US11634503B2 · kind B2 · utility
0Cited by
9References
23Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 4, 2020 |
| Grant date | Apr 25, 2023 |
| Priority date | — |
| Expiry date | Feb 9, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.